AMYT - Amryt Pharma GAAP EPS of -$0.02 beats by $0.04 revenue of $68.54M beats by $4.28M
- Amryt Pharma press release ( NASDAQ: AMYT ): Q2 GAAP EPS of -$0.02 beats by $0.04 .
- Revenue of $68.54M (+9.2% Y/Y) beats by $4.28M .
- Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth
- Stock repurchase program underway – board approved up to $30M through March 2023.
For further details see:
Amryt Pharma GAAP EPS of -$0.02 beats by $0.04, revenue of $68.54M beats by $4.28M